Monteverde & Associates Investigates Mergers of Alimera Sciences and ALLETE

The class action firm scrutinizes proposed mergers involving Alimera Sciences and ALLETE, focusing on shareholder interests.

Monteverde & Associates PC is investigating the merger of Alimera Sciences with ANI Pharmaceuticals.
Alimera Sciences shareholders to receive $5.50 per share plus contingent value rights based on future revenue targets.
The firm is also examining ALLETE's proposed merger with a partnership led by Canada Pension Plan Investment Board and Global Infrastructure Partners.
ALLETE stockholders will receive $67.00 per share in cash upon closing of the transaction.
The shareholder vote on the ALLETE merger is scheduled for August 21, 2024.